AU2021353055B2 - Crystalline forms of a pharmaceutical compound - Google Patents
Crystalline forms of a pharmaceutical compound Download PDFInfo
- Publication number
- AU2021353055B2 AU2021353055B2 AU2021353055A AU2021353055A AU2021353055B2 AU 2021353055 B2 AU2021353055 B2 AU 2021353055B2 AU 2021353055 A AU2021353055 A AU 2021353055A AU 2021353055 A AU2021353055 A AU 2021353055A AU 2021353055 B2 AU2021353055 B2 AU 2021353055B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- crystalline form
- disease
- pharmaceutical composition
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2022291486A AU2022291486B2 (en) | 2020-10-02 | 2022-12-20 | Crystalline forms of a pharmaceutical compound |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| EP20199934.9 | 2020-10-02 | ||
| PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022291486A Division AU2022291486B2 (en) | 2020-10-02 | 2022-12-20 | Crystalline forms of a pharmaceutical compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021353055A1 AU2021353055A1 (en) | 2022-09-15 |
| AU2021353055B2 true AU2021353055B2 (en) | 2022-10-06 |
Family
ID=72744696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021353055A Active AU2021353055B2 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
| AU2022291486A Active AU2022291486B2 (en) | 2020-10-02 | 2022-12-20 | Crystalline forms of a pharmaceutical compound |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022291486A Active AU2022291486B2 (en) | 2020-10-02 | 2022-12-20 | Crystalline forms of a pharmaceutical compound |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12116344B2 (enExample) |
| EP (3) | EP3978474A1 (enExample) |
| JP (2) | JP2023524169A (enExample) |
| KR (2) | KR20240056628A (enExample) |
| CN (1) | CN116390910A (enExample) |
| AU (2) | AU2021353055B2 (enExample) |
| BR (2) | BR122022018214A2 (enExample) |
| CA (1) | CA3193939C (enExample) |
| CL (1) | CL2023000943A1 (enExample) |
| DK (1) | DK4114826T3 (enExample) |
| ES (1) | ES2964105T3 (enExample) |
| FI (1) | FI4114826T3 (enExample) |
| IL (2) | IL301882B2 (enExample) |
| MA (1) | MA58885B1 (enExample) |
| MX (1) | MX2023003618A (enExample) |
| PE (1) | PE20240138A1 (enExample) |
| TW (1) | TW202229236A (enExample) |
| WO (1) | WO2022069709A1 (enExample) |
| ZA (1) | ZA202310184B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250120958A1 (en) * | 2022-01-10 | 2025-04-17 | Azafaros B.V. | Treatment of GM2 Gangliosidosis |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| WO2025162745A1 (en) | 2024-02-01 | 2025-08-07 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3314009A2 (en) * | 2015-06-24 | 2018-05-02 | Universiteit Leiden | Glycosylated metabolites |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 JP JP2022577645A patent/JP2023524169A/ja active Pending
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 TW TW110136766A patent/TW202229236A/zh unknown
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021353055B2 (en) | Crystalline forms of a pharmaceutical compound | |
| EA019819B1 (ru) | Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении | |
| JP2025511217A (ja) | メセンブリンの塩形態 | |
| US11834431B2 (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
| US20250120958A1 (en) | Treatment of GM2 Gangliosidosis | |
| NZ798892B2 (en) | Crystalline forms of a pharmaceutical compound | |
| HK40087007A (en) | Crystalline forms of a pharmaceutical compound | |
| HK40087007B (en) | Crystalline forms of a pharmaceutical compound | |
| EA045552B1 (ru) | Кристаллические формы фармацевтического соединения | |
| Lahiri et al. | Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in alzheimer disease | |
| WO2024263878A2 (en) | Solid forms of posiphen d-tartrate | |
| WO2025103313A1 (zh) | 靶向羟基类固醇17-β脱氢酶4的五环三萜化合物的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |